Curriculum · Metabolic and Endocrine and Diabetes Mellitus
Hypercalcaemia of malignancy
What it is
Malignancy-induced hypercalcemia is hypercalcemia that comes from the malignancy itself. Two mechanisms are proposed for it: paraneoplastic release of PTHrP, and osteolytic metastatic lesions.
Causes and risk
Four routes are separated, each with its own mediator and the malignancies in which it is seen:
- Humoral hypercalcaemia, through PTHrP, in SCC, breast, ovarian and HTLV-lymphoma.
- Local osteolytic hypercalcaemia, through cyto- and chemokine, in breast, MM and lymphoma.
- Vitamin D mediated, through 1,25(OH)2D, in lymphoma.
- Ectopic hormone secretion of PTH, in variable malignancies.
How it presents
The picture is an elderly chronic smoker with abdominal cramps, decreased urine output and constipation, who also gave a history of hemoptysis over months with cough and night sweats that point to the malignancy.
How it is diagnosed
A biochemical panel is sent, and the bedside test is an ECG, to assess the QTc interval.
The order of the laboratory work is what puts malignancy on the list in the first place. Hypercalcemia is confirmed first, by repeat testing and by correcting for the albumin concentration or measuring ionized calcium, and then the PTH level is measured, since PTH is the initial laboratory test that best determines the underlying etiology. A high-normal or elevated PTH makes the hypercalcemia PTH-dependent, and that group holds primary or tertiary hyperparathyroidism, familial hypocalciuric hypercalcemia and lithium. A suppressed PTH makes it PTH-independent, and PTHrP, 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D are then measured; the causes in that group are malignancy, vitamin D toxicity, granulomatous diseases, drug-induced hypercalcemia such as thiazides, milk-alkali syndrome, thyrotoxicosis, vitamin A toxicity and immobilization. So a suppressed PTH is what points at the malignancy, and lithium and thiazide are the two drugs named beside it.